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We assessed the diagnostic utility of the connective tissue disease (CTD) screen as an automated screening test, in comparison with
the indirect immunoﬂuorescence (IIF), EliA extractable nuclear antigen (ENA), and line immunoassay (LIA) for patients with
antinuclear antibody- (ANA-) associated rheumatoid disease (AARD). A total of 1115 serum samples from two university
hospitals were assayed using these four autoantibody-based methods. The AARD group consisted of patients with systemic
lupus erythematosus (SLE), systemic sclerosis (SSc), Sjögren’s syndrome (SS), and mixed connective tissue disease (MCTD). The
qualitative results of all four autoantibody assays showed a signiﬁcant association with AARDs, compared to controls (P <
0 0001 for all). The areas under the receiver operating characteristic curves (ROC-AUCs) of the CTD screen for diﬀerentiating
total AARDs, SLE, SSc, SS, and MCTD from controls were 0.89, 0.93, 0.73, 0.93, and 0.95, respectively. The ROC-AUCs of
combination testing with LIA were slightly higher in patients with AARDs (0.92) than those of CTD screen alone. Multivariate
analysis indicated that all four autoantibody assays could independently predict AARDs. CTD screening alone and in
combination with IIF, EliA ENA, and LIA are potentially valuable diagnostic approaches for predicting AARDs. Combining
CTD screen with LIA might be eﬀective for AARD patients.
1. Introduction
Autoantibodies are closely related to clinical manifestations
or the prognosis of patients with antinuclear antibody-
(ANA-) associated rheumatoid diseases (AARDs), including
systemic lupus erythematosus (SLE), systemic sclerosis
(SSc), Sjögren’s syndrome (SS), and mixed connective tissue
disease (MCTD), who generally suﬀer from diﬀuse organ
damage [1, 2]. Antinuclear antibodies (ANAs), a kind of
autoantibody, are directed against a variety of nuclear anti-
gens. The detection of ANAs is useful for diagnosing
patients with AARDs [3, 4]. Indirect immunoﬂuorescence
(IIF) assays with cultured human epithelial carcinoma cells
(HEp-2 cells) have been regarded as a gold standard method
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[5]. However, IIF is a labor-intensive and time-consuming
procedure and exhibits poor reproducibility due to the sub-
jective interpretation of results [4, 6].
Enzyme immunoassays (EIAs) have been developed as
alternatives to IIF for ANA screening and are widely used
in clinical laboratories, enabling automation and quantita-
tion of ANA screening [7]. The connective tissue disease
(CTD) screen (Phadia AB, Uppsala, Sweden) used in this
study is a recently introduced EIA-based assay employing
17 diﬀerent human recombinant antigens. After the initial
screen for ANAs, autoantibodies to extractable nuclear anti-
gen (ENA) are frequently detected because of their diagnostic
and prognostic signiﬁcance. Identiﬁcation of anti-ENA anti-
bodies plays a critical role in the diagnosis and management
of AARD [1, 8]. EliA ENA assays (Phadia AB) for detecting
autoantibodies to dsDNA, U1RNP, Sm, Ro/SSA, La/SSB,
Scl-70, Pm-scl, Jo-1, and CENP have been introduced in
the form of several diﬀerent EIA kits, and line immunoassays
(LIAs) have been widely applied for conﬁrmatory testing [9].
Little information is available regarding evaluation of the
performance of these autoantibody assays simultaneously
for autoantibodies and consequent antibody-disease associa-
tions. Further, most previous population studies involved
patients in Europe or the USA.
In this study, we evaluated the current diagnostic per-
formance of an automated CTD screening assay in patients
with AARDs. The diagnostic utility of the assay was com-
pared with that of the HEp-2 cell-based IIF, EliA ENA,
and LIA tests in a large Asian population. We also investi-
gated the diagnostic performance of the CTD screen in
combination with the other three autoantibody assays for
each AARD.
2. Materials and Methods
2.1. Study Design. A total of 1115 sera from patients who
visited two university hospitals in Korea for AARD eval-
uation were collected to demonstrate the diagnostic per-
formance of the CTD screen (Phadia AB, Uppsala,
Sweden), as well as IIF (Fluoro HEPANA test, MBL
Co., Nagoya, Japan), EliA ENA (Phadia AB), and LIA
(Euroimmun AG, Lübeck, Germany) testing. The samples
were collected randomly, and results from the same
patients were not included repeatedly. This study was
approved by the independent Institutional Review Board
of Severance Hospital and Kosin University Gospel Hos-
pital. Because residual serum samples were obtained from
patients during routine screening for the detection of
autoantibodies in our clinical laboratory, this study was
exempted from the requirement for informed patient
consent. The specimens were retrospectively classiﬁed
according to predeﬁned diagnoses as follows: total AARD
(n = 112), SLE (n = 67), SSc (n = 21), SS (n = 19), MCTD
(n = 5), and control (n = 1003). The total AARD value
was derived from the number of patients with SLE,
SSc, SS, or MCTD. The controls were consecutive
patients who consulted the rheumatology clinics and for
whom the rheumatologists considered it necessary to
request ANA testing. After work-ups, these patients were
diagnosed not to have AARDs.
All patients were diagnosed by specialized rheumatolo-
gists in the clinics of Severance Hospital and Kosin Uni-
versity Gospel Hospital, based on the criteria of the
American College of Rheumatology and Systemic Lupus
International Collaborating Clinics [10, 11] for SLE, the
American College of Rheumatology/European League [12]
for SSc, the American-European Consensus Classiﬁcation
[13] for SS, and Alarcon-Segovia and Cardiel [14] for
MCTD. The control group consisted of patients with sev-
eral nonsystemic rheumatic diseases, considering actual
clinical laboratory status.
2.2. IIF for ANAs. IIF microscopy on HEp-2 cells for ANAs
was performed using a commercially available Fluoro
HEPANA Kit (MBL Co.), according to the manufacturer’s
instructions. The serum samples were diluted with
phosphate-buﬀered saline to a 1 : 40 ratio. The procedures
for IIF were conducted as described previously [15].
2.3. CTD Screen. Testing with the CTD screen (Phadia AB)
was conducted on a Phadia 250 instrument (Phadia AB).
The assays were conducted according to the manufacturer’s
instructions, as described before [15, 16]. The previously
applied cutoﬀs were also used in this study; cutoﬀs greater
than 1.0 were considered positive, ratios ranging from 0.7
to 1.0 were equivocal, and values less than 0.7 were negative.
2.4. EliA ENA. Nine kinds of EliA ENA assays for detecting
autoantibodies against dsDNA, U1RNP, Sm, Ro/SSA, La/
SSB, Scl-70, Pm-scl, Jo-1, and CENP were performed using
the respective EliA ENA kits (Phadia AB) on a Phadia 250
instrument (Phadia AB). All procedures were conducted as
indicated in the manufacturer’s instructions. The procedures
followed were similar to those described above for the CTD
screen. The cutoﬀ value for dsDNA was 15 IU/ml, and that
for U1RNP, Sm, Ro/SSA, La/SSB, Scl-70, Pm-scl, Jo-1, and
CENP was 10U/ml.
2.5. LIA. The EUROLINE test (Euroimmun AG) enabled
detection of 14 autoantibodies against RNP, Sm, Ro/SSA60,
Ro/SSA52, La/SSB, Scl-70, Pm-Scl, Jo-1, CENP, PCNA,
nucleosomes, histones, ribosomal-P, and AMA-M2. These
antigens were detected as discrete lines on a nylon membrane
with a plastic backing. These strips were incubated sequen-
tially with sera, alkaline phosphatase-labeled anti-human
IgG antibodies, and substrate solution (containing nitroblue
tetrazolium chloride and 5-bromo-4-chloro-3-indolyl phos-
phate), according to the manufacturer’s instructions. Reac-
tion intensities were automatically interpreted using
Eurolinescan software (Euroimmun AG), similar to the pro-
cedures described in a previous report [17].
2.6. Statistical Analysis. Statistical analyses were performed
using PASW software, version 24.0 (formerly, SPSS Statis-
tics) (SPSS Inc., Chicago, IL, USA) and Analyse-it Method
Evaluation Edition software, version 2.26 (Analyse-it Soft-
ware Ltd., Leeds, UK). Comparisons using chi-squared test
and the Mann–Whitney U test were performed as described
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before [15]. Cohen’s kappa coeﬃcients were calculated to
estimate the agreement among the results of the CTD screen
and the other three autoantibody assays, and McNemar’s
test was also conducted. Receiver operating characteristic
(ROC) curves were plotted for data from the CTD screen
alone or in combination with the other assays, in order to
assess their diagnostic abilities to distinguish between the
AARD groups and the control group. The areas under the
ROC curves (ROC-AUCs) for the CTD screen and its com-
bination with the other three assays were compared. Binary
logistic regression analysis was performed to estimate the
ROC-AUCs for IIF and CTD screen combinations, similar
to the previously described method [15, 18]. Multivariate
logistic regression analysis was performed by setting the
presence of an AARD as the dependent variable and age,
sex, and the results of IIF, CTD screen, EliA ENA, and LIA
testing as covariables. P values less than 0.05 were consid-
ered statistically signiﬁcant.
3. Results
3.1. Study Population Characteristics. The basic characteris-
tics of the study population are presented in Table 1. The
median ages of patients in the total AARD and control
groups were 39.0 and 50.0 years, respectively (P < 0 0001).
The proportion of female patients between the total AARD
and control group was not signiﬁcant (97.3% versus 99.2%,
P = 0 0561).
3.2. Comparison of the CTD Screen, IIF, EliA ENA, and LIA
Results according to Predeﬁned AARD Criteria. The qualita-
tive results of the CTD screen, IIF, EliA ENA, and LIA tests
in patients with predeﬁned AARDs and control subjects are
summarized in Table 1. The results from all four assays were
signiﬁcantly associated with the total AARD group, com-
pared to the control group (P < 0 0001 for all) (Table 1).
3.3. Overall Agreement among the CTD Screen, IIF, EliA ENA,
and LIA Test Results according to the AARD Groups.An over-
all comparison of the results, including the concordance
rates, kappa coeﬃcient, and P values of McNemar testing,
among the four autoantibody assays is presented in Table 2.
3.3.1. Concordance Rates. When the CTD screen ratios were
considered as qualitative results with a cutoﬀ of 1.0 (equivo-
cal ratios scored as negative results), as suggested by the man-
ufacturer, the overall concordance rates were 80.4% for the
CTD screen versus IIF, 89.3% versus EliA ENA, and 79.5%
versus LIA in the total AARD group. In addition, the overall
concordance rates were 78.6% for the CTD screen with a cut-
oﬀ of 0.7 (equivocal ratios scored as positive results) versus
IIF, 89.3% versus EliA ENA, and 81.3% versus LIA.
3.3.2. Kappa Coeﬃcients. The kappa coeﬃcients between
the CTD screen and EliA ENA were good (0.70), while
those between the CTD screen and IIF were moderate
(0.47 for cutoﬀ 1.0 and 0.41 for cutoﬀ 0.7), and those
between the CTD screen and LIA were fair (0.29 for cut-
oﬀ 1.0 and 0.32 for cutoﬀ 0.7).
3.3.3. McNemar Test. The P values of McNemar tests showed
no statistically signiﬁcant diﬀerences between the CTD
screen and LIA (0.6776 for cutoﬀ 1.0 and 1.0000 for cutoﬀ
0.7), whereas the diﬀerences between the CTD screen versus
IIF (0.0169 for cutoﬀ 1.0 and 0.0066 for cut-oﬀ 0.7) and CTD
screen versus EliA ENA (0.0063 for cutoﬀ 1.0 and 0.0005 for
cutoﬀ 0.7) were signiﬁcant in the total AARD group.
3.4. Diagnostic Performances of the CTD Screen, IIF, EliA
ENA, and LIA Tests. The calculated ROC-AUCs, sensitivities,
speciﬁcities at the best cutoﬀs, likelihood ratios, and odds
ratios are shown in Table 3.
3.4.1. ROC-AUCs. The best cutoﬀ was determined when the
sum of sensitivity and speciﬁcity was maximized. When
these cut-oﬀ values were applied, the sensitivities of the
CTD screen and its combination with IIF, EliA ENA,
and LIA were 81.3%, 85.7%, 83.0%, and 92.9%, respec-
tively, and the speciﬁcities were 92.1%, 85.2%, 89.6%, and
83.7%, respectively, in the total AARD group. The ROC-
AUCs of the CTD screen and its combination with IIF,
EliA ENA, and LIA were over 0.90 for all subgroups, indi-
cating excellent diagnostic performances, except for the
ROC-AUCs in the SSc group, which showed fair perfor-
mance (Figure 1). The diﬀerences between the ROC curves
of the CTD screen and its combinations when diﬀerentiat-
ing AARDs from the control group were also analyzed.
The ROC-AUCs for CTD screen and its combination with
LIA were 0.89 and 0.92, respectively, demonstrating a sig-
niﬁcant diﬀerence (P = 0 0267) in the total AARD group,
while the other combinations in the total AARD group,
as well as in the SLE, SSc, SS, and MCTD groups, did
not show signiﬁcant diﬀerences.
3.4.2. Likelihood Ratio and Odds Ratio. The positive and
negative likelihood ratios of the CTD screen and its com-
bination with IIF, EliA ENA, and LIA in the total AARD,
SLE, SS, and MCTD groups were considered very useful
(positive likelihood ratio> 5.0 or ≤0.2 for all groups).
The positive likelihood ratios for the CTD screen and its
combination with IIF, EliA ENA, and LIA in the SSc
group were also very useful, while the negative likelihood
ratios among them ranged from 0.3 to 0.4, indicating that
they were just useful, based on the criteria of Solomon
et al. [4]. Additionally, the odds ratios of CTD screen
with LIA (67.0) were marginally higher than those of
CTD screen alone (50.7) in the total AARD group.
3.5. Multivariate Analysis of CTD Screen, IIF, EliA ENA, and
LIA Test Results.Multivariate analysis was performed using
the presence of an AARD as the binary dependent vari-
able and age and sex of the patient and the CTD screen,
IIF, EliA ENA, and LIA results as predictors. We found
that age and the results from CTD screen, IIF, EliA
ENA, and LIA testing were independently associated with
total AARD (Table 4). Our results showed that age, CTD
screen, IIF, and LIA results for SLE; age, sex, IIF, and
LIA results for SSc; and EliA ENA and LIA results for
SS independently correlated with the respective rheumatic
diseases. Sex was not a predictor in the SS and MCTD
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groups in the multivariate analysis because all subjects
were female.
4. Discussion
Diagnostic applications of the CTD screen was assessed
in Korean patients with AARDs, retrospectively. The per-
formance of an automated screening assay was compared
to HEp-2 cell-based IIF, EliA ENA, and LIA methods. In
addition, diagnostic values of combining the CTD screen
and these 3 autoantibody assays were investigated for
each AARD.
The proportions of CTD screen, IIF, EliA ENA, and
LIA positivities were higher in patients diagnosed with
AARDs than in the control group, indicating that these
four assays would be useful for detecting the patients with
AARDs. Previous reports have shown similar results with
these assays [19–22]. The sensitivities and speciﬁcities of
these four assays would be aﬀected because the classiﬁca-
tion criteria of each AARD were applied to our study as a
standard. Regarding the sensitivity of the HEp-2 IIF, the
values in this study were considerably low when compared
to those in the previous reports [23, 24]. Meanwhile, there
are several studies with decreased sensitivities of HEp-2
IIF such as 69.0%, 36.4%, and 53.7% [16, 22, 25], even
lower than those of our study. Although our laboratory
obtained accreditation, tested kits, condition of micro-
scopes, interobserver variations, and low number of the
patient population may have an inﬂuence on the values,
similar to these studies with lowered sensitivities.
The negative results in the AARD groups were caused
by earlier clinical observations and subsequent development
of positivity in follow-up or a negative conversion after ini-
tial positivity at presentation because of immunosuppres-
sive treatment, based on a review of each medical chart.
Clinical and serological presentations can ﬂuctuate over
time in AARD patients, according to the results of several
studies [19, 26].
Regarding the overall concordance rates between the
CTD screen and IIF test, the agreements ranged from 87%
to 95% when comparing the EIA assays and IIF in a previous
study [27]. Previously, Cohen’s kappa value observed when
combining EIA results of ENA and IIF tests was reported to
be 0.30 [19], which was the same as that found with com-
bined EliA ENA and IIF testing (0.30) and lower than that
of the CTD screen and the IIF test (0.70), in this study. The
previous report showed that the EIA for ENA and IIF results
exhibited fair agreement for patients with SLE and that the
kappa agreement for patients with scleroderma was good.
Our results also demonstrated that the kappa value between
EliA ENA and IIF of the SSc group (0.45) was higher than
that of the SLE group (0.34). The kappa values between the
CTD screen and IIF test were higher than those of EliA
ENA and IIF in all subgroups, indicating that the CTD screen
was more appropriate for screening with more diverse anti-
gens than the EliA ENA test.
With respect to the LIA results, the kappa coeﬃcients
compared to IIF were similar to the previous results in
the total AARD group (0.45 versus 0.404), as well as the
SLE (0.28 versus 0.298) and SSc (0.48 versus 0.573) groups
[28]. These agreements between the LIA and IIF methods
were also similar to those between the LIA test and CTD
screen, reﬂecting the characteristics of CTD screen and
IIF as screening assays. There were slight diﬀerences
between the diﬀerent study populations and the cutoﬀ
used for each method. A detailed description of the agree-
ments found between these tests (including concordance
rates, Cohen’s kappa values, and P values for McNemar
tests) among the widely used autoantibody assays has been
scarcely reported in the literature with large groups.
The diagnostic abilities of the CTD screen to discrim-
inate each AARD subgroup from the control group were
analyzed because the clinical utility of the CTD screen
Table 1: Demographic characteristics of the study population and the qualitative values for four autoantibody assays.
Variables
Total AARD
(n = 112)
SLE
(n = 67)
SSc
(n = 21)
SS
(n = 19)
MCTD
(n = 5)
Control
(n = 1003) P value
∗
Age (years)∗∗ 39.0
(23.0–51.0)
37.0
(17.2–44.8)
39.0
(26.7–49.7)
54.0
(42.0–62.0)
43.0
(35.0–47.3)
50.0
(37.0–61.0)
<0.0001
Number of females, % 109, 97.3 66, 98.5 19, 90.5 19, 100.0 5, 100.0 995, 99.2 0.0561
CTD screen, cutoﬀ ratio
0.7 (number), %
Positive 93, 83.0 58, 86.6 13, 61.9 17, 89.5 5, 100.0 100, 10.0 <0.0001
Negative 19, 17.0 9, 13.4 8, 38.1 2, 10.5 0, 0.0 903, 90.0
CTD screen, cutoﬀ ratio
1.0 (number), %
Positive 91, 81.3 57, 85.1 13, 61.9 16, 84.2 5, 100.0 79, 7.9 <0.0001
Negative 21, 18.7 10, 14.9 8, 38.1 3, 15.8 0, 0.0. 924, 92.1
HEp-2 IIF (number), %
Positive 79, 70.5 51, 76.1 13, 61.9 11, 57.9 4, 80.0 99, 9.9 <0.0001
Negative 33, 29.5 16, 23.9 8, 38.1 8, 42.1 1, 20.0 904, 90.1
EliA ENA (number), %
Positive 81, 72.3 51, 76.1 9, 42.9 17, 89.5 4, 80.0 93, 9.3 <0.0001
Negative 31, 27.7 16, 23.9 12, 57.1 2, 10.5 1, 20.0 910, 90.7
LIA (number), %
Positive 94, 83.9 58, 86.6 14, 66.7 18, 94.7 4, 80.0 141, 14.1 <0.0001
Negative 18, 16.1 9, 13.4 7, 33.3 1, 5.3 1, 20.0 862, 85.9
AARD: antinuclear antibody-associated rheumatoid disease; SLE: systemic lupus erythematosus; SSc: systemic sclerosis; SS: Sjögren’s syndrome; MCTD: mixed
connective tissue disease; IIF: indirect immunoﬂuorescence; ENA: extractable nuclear antigen; LIA: line immunoassay. ∗Chi-squared test for nominal variables
and Mann–Whitney U test for continuous variables in the total AARD group versus control. ∗∗Data are expressed as the median (1st to 3rd quartiles).
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can vary with the characteristics of AARD patients and
nonrheumatic conditions. The portion of SSc patients in
the total AARD group may explain the lower CTD screen
performance in the total AARD group, based on the ROC-
AUCs. A previous study was conducted to evaluate auto-
mated ENA screening assay with 9 antigens and showed
an ROC-AUC of 0.823, sensitivity of 63%, and speciﬁcity
of 91% for AARD patients [22], which were slightly lower
than the values obtained in our study. Another previous
report showed that the sensitivities of the CTD screen
for SLE, SSc, SS, and MCTD groups were 74%, 72%,
89%, and 100%, respectively [20]. Although the sensitivi-
ties reported for previous studies and those of our study
were slightly diﬀerent, the highest sensitivity for the
MCTD group and lowest sensitivity for the SSc group
[20] were concordant to our study. With respect to the
cutoﬀs, we described the CTD screen results at 0.7 and
1.0 because these values are suggested by the manufac-
turer’s instructions. Based on the best cutoﬀ of ROC-
AUCs in our study, 1.0 of CTD screen is closer to it than
0.7 for total AARD, SLE, SSc, and MCTD and vice versa
for SS. Therefore, 1.0 would be the best cutoﬀ for patients
with AARD, including SLE, SSc, and MCTD while 0.7
would be more appropriate for patients with SS. After ver-
iﬁcation, applying the optimal cutoﬀ for each clinical lab-
oratory is recommended.
Regarding clinical implications based on our data, CTD
screen was comparable to IIF or the other assays because
the 95% conﬁdence intervals (CIs) of sensitivities and
ROC-AUCs were overlapped with those in the others, indi-
cating no statistical signiﬁcance. Further, CTD screen
exhibited slightly better speciﬁcity than the other assays
according to the results of Tables 1 and 3, raising the pos-
sibility of an alternative screening assay. However, suﬃcient
review of previous literatures for ANA testing [5, 29] is
necessary when these assays are adopted to individual clin-
ical laboratories. A variety of confounding factors such as
patient populations, controls, applied methods, and cutoﬀs
might aﬀect the analyzed results.
The positive likelihood ratios of the CTD screen were
very useful and conclusive, with respect to pretest and
posttest probabilities [4, 30]. Previously published data
also demonstrated positive results for the CTD screen at
a cutoﬀ of 1.0, with positive likelihood ratios greater than
5.0 in the SLE, SSc, SS, and MCTD groups [20]. The
negative likelihood ratios for the CTD screen were less
than 0.2 with the exception of SSc patients. Op De Beeck
et al. [20] showed a similar pattern for the CTD screen
in patients with SLE (0.3), SSc (0.3), and SS (0.1), which
was considered to be very useful or useful tests, based on
the negative likelihood ratios [4].
Based on the values of ROC-AUCs and odds ratios,
concurrent determination with the CTD screen and LIA
test demonstrated slightly improved diagnostic utilities
in patients in the total AARD group, compared to the
CTD screen alone. According to a previous report, the
diagnostic performance of the CTD screen was signiﬁ-
cantly improved when used in combination with IIF,
based on the likelihood ratios and ROC-AUCs [31].
The study population was patients of the university hos-
pital in Belgium, and the results were slightly varied
according to the diagnosis, suggesting diﬀerent strategies
for each AARDs. Therefore, uniformed and simultaneous
screening by the CTD screen and IIF [29] would not be
eﬀective in cases with strong clinical manifestations asso-
ciated with each AARD. Further, investigating laboratory
ﬁndings with respect to other immunologic disorders
might be essential for diagnosing each AARD when the
screening assay shows positive results.
Multivariate analysis was also conducted for age and
sex to assess CTD screen, IIF, EliA ENA, and LIA results
as predictor variables for AARD groups and to control
for potential confounding factors. ANAs were previously
found in healthy individuals, particularly women older
than 40 years [32]. Therefore, the factors of age and sex
were incorporated into our multivariate model. The mul-
tivariate analysis results revealed that CTD screen, IIF,
EliA ENA, and LIA results were independently related
to the total AARD group, indicating that these four auto-
antibody assays could be applied for diagnosing AARDs.
However, not all assays showed signiﬁcant P values in
the subgroups. Based on our multivariate analysis, a com-
bination with LIA for diagnostic work-ups of patients
with SSc or SS would be necessary, when the CTD screen
was applied to the clinical laboratories.
The proﬁles for the individual autoantibodies in the
EliA ENA and LIA tests were generally concordant with
previous reports [17, 28]. The high speciﬁcities of EliA
ENA and LIA for individual autoantibodies (over 95.0%)
were similar to those of a previous study, which showed
at least 97% speciﬁcities [17]. These assays, especially
the LIA, have been used as conﬁrmatory tests, based on
their high speciﬁcities [9]. The relatively low speciﬁcities
of anti-Ro/SSA and Scl-70, which are related to SS and
SSc, respectively [17, 24], might contribute to the lowered
speciﬁcities of LIA.
Our study design has some limitations in that most of
our study population was composed of females, especially
the SS and MCTD groups. Among the hospitalized SLE
patients, 165 out of 180 (91.8%) were female, based on
the information in the Korean lupus network registry
[33]. Although our data reﬂected a predominant portion
of female patients, further studies involving male patients
should be followed. Moreover, the number of patient pop-
ulation was small, especially MCTD, because of low preva-
lence. Further studies involving large study populations are
necessary, considering the statistical power, interpretation,
and application of the results to AARD patients.
5. Conclusions
In conclusion, we evaluated the diagnostic utilities of
CTD screen, IIF, EliA ENA, and LIA testing to predict
AARDs. Although a few published reports have dis-
cussed the usefulness of the CTD screen alone, no report
has assessed a large population of Korean patients in
Asia or the diagnostic performance of these frequently
used autoantibody assays for AARDs in current use.
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CTD screening and the other three assays are potentially
valuable diagnostic tools for detecting AARDs. In partic-
ular, the CTD screen showed considerable diagnostic
performance for patients with SLE rather than SSc, and
its combination with the LIA test might be more eﬀec-
tive for diagnosing total AARDs than the CTD screen
alone. Our results provided recent information regarding
the CTD screen, IIF, EliA ENA, and LIA methods for
testing patients with AARDs to facilitate appropriate
patient management, with cautious clinical impressions
of patients’ diagnosis.
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Table 3: ROC-AUC, sensitivity, and speciﬁcity of the CTD screen, tested independently and in combination.
Predeﬁned diseases Parameter CTD screen CTD screen + IIF CTD screen + EliA ENA CTD screen + LIA
Total AARD (n = 112)
ROC-AUC∗ 0.89 (0.85–0.93) 0.89 (0.85–0.93) 0.89 (0.85–0.93) 0.92 (0.88–0.95)
P value∗ <0.0001 <0.0001 <0.0001 <0.0001
Sensitivity (%)∗ 81.3 (72.8–88.0) 85.7 (77.8–91.6) 83.0 (74.8–89.5) 92.9 (86.4–96.9)
Speciﬁcity (%)∗ 92.1 (90.3–93.7) 85.2 (82.9–87.4) 89.6 (87.6–91.4) 83.7 (81.3–86.0)
+LR 10.3 5.8 8.0 5.7
−LR 0.2 0.2 0.2 0.1
Odds ratio 50.7 (29.9–85.9) 34.7 (19.9–60.5) 42.3 (24.8–72.1) 67.0 (32.0–140.2)
SLE (n = 67)
ROC-AUC∗ 0.93 (0.88–0.97) 0.92 (0.88–0.97) 0.92 (0.88–0.96) 0.95 (0.91–0.98)
P value∗ <0.0001 <0.0001 <0.0001 <0.0001
Sensitivity (%)∗ 85.1 (74.3–92.6) 80.6 (69.1–89.2) 88.1 (77.8–94.7) 95.5 (87.5–99.1)
Speciﬁcity (%)∗ 93.7 (92.0–95.1) 95.7 (94.3–96.9) 88.3 (86.2–90.3) 83.8 (81.4–86.1)
+LR 13.5 18.8 7.6 5.9
−LR 0.2 0.2 0.1 0.1
Odds ratio 85.0 (41.4–174.5) 92.7 (47.1–182.7) 55.8 (26.0–119.8) 110.7 (34.4–356.8)
SSc (n = 21)
ROC-AUC∗ 0.73 (0.58–0.88) 0.75 (0.59–0.90) 0.72 (0.57–0.87) 0.76 (0.61–0.91)
P value∗ 0.0017 0.0011 0.0018 0.0003
Sensitivity (%)∗ 61.9 (38.4–81.9) 71.4 (47.8–88.7) 61.9 (38.4–81.9) 76.2 (52.8–91.8)
Speciﬁcity (%)∗ 92.5 (90.7–94.1) 87.2 (85.0–89.2) 90.6 (88.7–92.4) 85.2 (82.9–87.4)
+LR 8.3 5.6 6.6 5.2
−LR 0.4 0.3 0.4 0.3
Odds ratio 20.1 (8.1–50.0) 17.1 (6.5–44.8) 15.7 (6.4–38.9) 18.5 (6.7–51.2)
SS (n = 19)
ROC-AUC∗ 0.93 (0.87–0.99) 0.93 (0.88–0.98) 0.94 (0.88–0.99) 0.97 (0.95–0.99)
P value∗ <0.0001 <0.0001 <0.0001 <0.0001
Sensitivity (%)∗ 89.5 (66.9–98.7) 94.7 (74.0–99.9) 89.5 (66.9–98.7) 100.0 (82.4–100.0)
Speciﬁcity (%)∗ 90.7 (88.8–92.5) 83.7 (81.3–86.0) 91.7 (89.8–93.4) 85.1 (82.8–87.3)
+LR 9.7 5.8 10.8 6.7
−LR 0.1 0.1 0.1 0.0
Odds ratio 83.2 (18.9–365.6) 92.8 (12.3–699.7) 94.2 (21.4–414.8) NC
MCTD (n = 5)
ROC-AUC∗ 0.95 (0.92–0.98) 0.95 (0.90–100.0) 0.94 (0.91–0.98) 0.94 (0.89–100.0)
P value∗ <0.0001 <0.0001 <0.0001 <0.0001
Sensitivity (%)∗ 100.0 (47.8–100.0) 100.0 (47.8–100.0) 100.0 (47.8–100.0) 100.0 (47.8–100.0)
Speciﬁcity (%)∗ 92.1 (90.3–93.7) 85.2 (82.9–87.4) 90.5 (88.5–92.3) 83.5 (81.1–85.8)
+LR 12.7 6.8 10.6 6.1
−LR 0.0 0.0 0.0 0.0
Odds ratio NC NC NC NC
ROC-AUC: areas under the receiver operating characteristic curve; IIF: indirect immunoﬂuorescence; ENA: extractable nuclear antigen; LIA: line
immunoassay; LR: likelihood ratio; AARD: antinuclear antibody-associated rheumatoid disease; SLE: systemic lupus erythematosus; SSc: systemic
sclerosis; SS: Sjögren’s syndrome; MCTD: mixed connective tissue disease; NC: not calculated. ∗Data are shown with the 95% conﬁdence interval
in parentheses, and the P values presented for the ROC-AUCs were greater than 0.5.
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Figure 1: Diagnostic performance of the CTD screen, tested independently and in combination with autoantibody assays. (a) Receiver
operating characteristic (ROC) curves of the CTD screen (0.89) and its combination with autoantibody assays for discriminating total
antinuclear antibody-associated rheumatoid disease patients (n = 112) from control subjects (n = 1003); (b) ROC curves for the CTD
screen (0.93) and its combination with autoantibody assays, diﬀerentiating patients with systemic lupus erythematosus (SLE) (n = 67)
from control subjects; (c) ROC curves for the CTD screen (0.73) combined with autoantibody assays, diﬀerentiating patients with systemic
sclerosis (SSc) (n = 21) from control subjects; (d) ROC curves for the CTD screen (0.93) and its combination with autoantibody assays,
discriminating patients with Sjögren’s syndrome (SS) (n = 19) from control subjects; (e) ROC curves for the CTD screen (0.95) and its
combination with autoantibody assays, diﬀerentiating patients with mixed connective tissue disease (MCTD) (n = 5) from control subjects.
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